Literature DB >> 18489513

Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI).

Garry R Barton1, Andrew H Briggs, Elisabeth A L Fenwick.   

Abstract

OBJECTIVE: To demonstrate how the optimal decision and level of uncertainty associated with that decision, can be presented when assessing the cost-effectiveness of multiple options. To explore and explain potentially counterintuitive results that can arise when analyzing multiple options.
METHODS: A template was created, based on the assumption of multivariate normality, in order to replicate a previous analysis that compared the cost-effectiveness of multiple options. We used this template to explain some of the different shapes that the cost-effectiveness acceptability curve (CEAC), cost-effectiveness acceptability frontier (CEAF), and expected value of perfection information (EVPI) may take, with changing correlation structure and variance between the multiple options.
RESULTS: We show that it is possible for 1) an option that is subject to extended dominance to have the highest probability of being cost-effective for some values of the cost-effectiveness threshold; 2) the most cost-effective (optimal) option to never have the highest probability of being cost-effective; and 3) the EVPI to increase when the probability of making the wrong decision decreases. Changing the correlation structure between multiple options did not change the presentation of results on the cost-effectiveness plane.
CONCLUSION: The cost-effectiveness plane has limited use in representing the uncertainty surrounding multiple options as it cannot represent correlation between the options. CEACs can represent decision uncertainty, but should not be used to determine the optimal decision. Instead, the CEAF shows the decision uncertainty surrounding the optimal choice and this can be augmented by the EVPI to show the potential gains to further research.

Entities:  

Mesh:

Year:  2008        PMID: 18489513     DOI: 10.1111/j.1524-4733.2008.00358.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  98 in total

1.  Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.

Authors:  Laura McCullagh; Cathal Walsh; Michael Barry
Journal:  Pharmacoeconomics       Date:  2012-10-01       Impact factor: 4.981

Review 2.  Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.

Authors:  Christine M Nguyen; Mark Bounthavong; Margaret A S Mendes; Melissa L D Christopher; Josephine N Tran; Rashid Kazerooni; Anthony P Morreale
Journal:  Pharmacoeconomics       Date:  2012-07-01       Impact factor: 4.981

Review 3.  Conducting economic evaluations of screening and brief intervention for hazardous drinking: Methods and evidence to date for informing policy.

Authors:  Alexander J Cowell; Jeremy W Bray; Michael J Mills; Jesse M Hinde
Journal:  Drug Alcohol Rev       Date:  2010-11

4.  Output correlations in probabilistic models with multiple alternatives.

Authors:  Klemen Naveršnik
Journal:  Eur J Health Econ       Date:  2014-01-04

5.  The influence of waiting times on cost-effectiveness: a case study of colorectal cancer mass screening.

Authors:  Pauline Chauvin; Jean-Michel Josselin; Denis Heresbach
Journal:  Eur J Health Econ       Date:  2013-08-22

6.  Cost-effectiveness of primary prevention of paediatric asthma: a decision-analytic model.

Authors:  G Feljandro P Ramos; Antoinette D I van Asselt; Sandra Kuiper; Johan L Severens; Tanja Maas; Edward Dompeling; J André Knottnerus; Onno C P van Schayck
Journal:  Eur J Health Econ       Date:  2013-10-06

7.  "Time Traveling Is Just Too Dangerous" but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier.

Authors:  Fernando Alarid-Escudero; Eva A Enns; Karen M Kuntz; Tzeyu L Michaud; Hawre Jalal
Journal:  Value Health       Date:  2019-05       Impact factor: 5.725

8.  Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.

Authors:  Simon Eckermann; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-07       Impact factor: 4.981

9.  Incremental net benefit and acceptability of alternative health policies: a case study of mass screening for colorectal cancer.

Authors:  Pauline Chauvin; Jean-Michel Josselin; Denis Heresbach
Journal:  Eur J Health Econ       Date:  2011-02-09

10.  Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting.

Authors:  Taru A Hallinen; Erkki J O Soini; Kari Eklund; Kari Puolakka
Journal:  Rheumatology (Oxford)       Date:  2010-01-25       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.